Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 833
- Registration Number
- NCT00936897
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00936988
PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 305
- Registration Number
- NCT00928408
Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 358
- Registration Number
- NCT00925587
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Phase 3
Completed
- Conditions
- CataractLow Bone Mineral DensityOsteopeniaOsteoporosisProstate CancerCancer
- Interventions
- Biological: DenosumabBiological: Placebo
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 769
- Registration Number
- NCT00925600
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Phase 3
Completed
- Conditions
- CancerColon CancerColorectal CancerFeverLocally AdvancedMetastatic Colorectal CancerNeutropeniaRectal Cancer
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 847
- Registration Number
- NCT00911170
- Locations
- 🇺🇦
Research Site, Uzhgorod, Ukraine
Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Phase 2
Completed
- Conditions
- Fracture Healing
- Interventions
- Drug: PlaceboBiological: Romosozumab
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 402
- Registration Number
- NCT00907296
- Locations
- 🇬🇧
Research Site, Stanmore, United Kingdom
IMPACT Non Hodgkins Lymphoma (NHL) Study
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Other: No intervention
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1837
- Registration Number
- NCT00903812
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 69
- Registration Number
- NCT00902356
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Phase 2
Completed
- Conditions
- Hypercalcemia of MalignancyHead and Neck CancerMetastatic CancerRenal CancerEndocrine CancerKidney CancerLymphomaBreast CancerColon CancerParathyroid Neoplasms
- Interventions
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 33
- Registration Number
- NCT00896454
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
© Copyright 2025. All Rights Reserved by MedPath